Cargando…

Abciximab: Abciximab-induced alveolar haemorrhage: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211963/ http://dx.doi.org/10.1007/s40278-021-97471-2

Ejemplares similares

Alveolar Hemorrhage during Abciximab Infusion
por: Koza, Yavuzer, et al.
Publicado: (2021)

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report
por: Kul, Selim, et al.
Publicado: (2017)

Be aware of misdiagnosis tied to COVID-19 focusing: a case report of abciximab-induced alveolar haemorrhage thought to be SARS-CoV-2 in a patient with ST-segment elevation myocardial infarction
por: Turan, Turhan, et al.
Publicado: (2020)

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
por: Vergara-Jimenez, Jennifer, et al.
Publicado: (2010)

Abciximab: a reappraisal of its use in coronary care
por: Valgimigli, Marco, et al.
Publicado: (2008)

Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab
por: Moon, Su-Jin, et al.
Publicado: (2008)

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion
por: Bertuglia, Silva, et al.
Publicado: (2002)

Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine Coronary Restenosis Model
por: Hong, Young Joon, et al.
Publicado: (2007)

A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab.
por: Jeong, M. H., et al.
Publicado: (2001)

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
por: Park, Soonyoung, et al.
Publicado: (2013)

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio
por: Voisard, Rainer, et al.
Publicado: (2006)

Intracoronary versus Intravenous Administration of Abciximab in Patients with Acute Coronary Syndrome: A Meta-Analysis
por: Wang, Jie-Ning, et al.
Publicado: (2013)

Effect of Abciximab on the Levels of Circulating Microparticles in Patients with Acute Myocardial Infarction Treated by Primary Angioplasty
por: Cha, Jung-Joon, et al.
Publicado: (2013)

Relationship between the duration of ischemia and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012)

Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012)

High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI – The Tamip Study
por: Balghith, Mohammed A.
Publicado: (2012)

Spontaneous Bleeding from Internal Pudendal Artery associated with Abciximab after Primary Percutaneous Coronary Intervention: Successful Treatment with Percutaneous Gel-Foam Embolization
por: Lee, Seung-Eun, et al.
Publicado: (2016)

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells
por: Pathak, Alokkumar, et al.
Publicado: (2008)

Efficacy of Femoral Vascular Closure Devices in Patients Treated with Anticoagulant, Abciximab or Thrombolytics during Percutaneous Endovascular Procedures
por: Kim, Ha Young, et al.
Publicado: (2006)

Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis
por: Wu, Yihua, et al.
Publicado: (2011)

Effect of a Dual Drug-Coated Stent With Abciximab and Alpha-Lipoic Acid in a Porcine Coronary Restenosis Model
por: Lim, Kyung Seob, et al.
Publicado: (2011)

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome
por: Shakoor, Muhammad Tariq, et al.
Publicado: (2014)

Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact
por: Rgeeb, Ahmed N., et al.
Publicado: (2020)

Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction
por: Morales-Ponce, Francisco J., et al.
Publicado: (2021)

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)

Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives
por: Dziewierz, Artur, et al.
Publicado: (2014)

Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy
por: Parodi, Guido, et al.
Publicado: (2010)

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
por: Namazi, Mohammad Hasan, et al.
Publicado: (2013)

Microvascular obstruction after successful fibrinolytic therapy in acute myocardial infarction. Comparison of reteplase vs reteplase+abciximab: A cardiovascular magnetic resonance study
por: ZONI, ANTONELLO, et al.
Publicado: (2006)

Efficacy of Combination Treatment with Intracoronary Abciximab and Aspiration Thrombectomy on Myocardial Perfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Stenting
por: Ahn, Sung Gyun, et al.
Publicado: (2014)

Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry)
por: Dziewierz, Artur, et al.
Publicado: (2012)

Clopidogrel: Diffuse alveolar haemorrhage: case report
Publicado: (2021)

Bevacizumab: Diffuse alveolar haemorrhage: case report
Publicado: (2015)

The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro(®)) Coated Stent in Patients with Coronary Artery Disease
por: Kim, Weon, et al.
Publicado: (2004)

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
por: Gu, Youlan L, et al.
Publicado: (2009)

Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials
por: Bai, Nan, et al.
Publicado: (2022)

Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
por: Sim, Doo Sun, et al.
Publicado: (2003)

Hyaluronic-acid: Diffuse alveolar haemorrhage and myocardial infarction: case report
Publicado: (2022)

Unilateral diffuse alveolar haemorrhage with microscopic polyangiitis: A case report
por: Kim, Tae Gyoung, et al.
Publicado: (2023)

A Suspected Case of an Alveolar Haemorrhage Caused by Dasatinib
por: Sakoda, Yoritake, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j6tg5u47nn1ptkn7mui9a2d95b